Clinical trials: Antibody
Nasopharyngeal Neoplasms
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT04870905
- Testing
- Tis-U-Sol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
This phase I trial studies the side effects and best dose of everolimus when given together with anakinra or denosumab in treating participants with cancers that have spread to other places in the body and have come back or…
- Conditions
- Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
- Trial name
- NCT01624766
- Testing
- Anakinra, Denosumab, Everolimus
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Acne Vulgaris
A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.
- Trial name
- NCT07449156
- Testing
- HB0043
- Where
- China
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Tetanus
Tdap Vaccine Safety for Plasma Donors
This is a prospective, open label, single-arm, multi-center, Phase 1 study measuring the safety and tetanus antibody responses to Tdap vaccine administered to plasma donors every 3 months ±1 week for 12 months (5 vaccinations)…
- Trial name
- NCT04142983
- Testing
- Adacel
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GCAM Inc.
Advanced Solid Tumor
A Study of SHR-A1403 in Patients With Advanced Solid Tumor
SHR-A1403 is a humanized IgG2, anti-C-Met monoclonal antibody conjugated to microtubule inhibitor (c-Met ADC).The aim of this study is to assess the safety and tolerability of SHR-A1403，to define the dose limited toxicity（DLT）and…
- Trial name
- NCT03856541
- Testing
- SHR-A1403
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Brain and Central Nervous System Tumors, Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00002754
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Breast Cancer Invasive
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
The primary aim is to evaluate the efficacy of neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy in patients with triple-negative breast cancer, with the endpoint being the pCR rate-defined as the…
- Trial name
- NCT06691594
- Testing
- neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ANCA-associated Vasculitides
Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
MAINRITSAN study compared Rituximab and azathioprine as maintenance therapy for ANCA-associated vasculitides. In this study, Rituximab (5 infusions at D1, D15, M6, M12, M18) was superior to azathioprine (2 mg/kg/day) to prevent…
- Trial name
- MAINRITSAN3 (NCT02433522)
- Testing
- rituximab
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma, Acral Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
This is a prospective, multicenter, open-label, 1:1 randomized phase II trial enrolling 76 patients with AJCC stage III surgically resectable acral melanoma.
- Trial name
- NCT07854522
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus)
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
IgG4 Related Disease, Systemic Sclerosis (SSc)
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
Immune-mediated inflammatory diseases (IMIDs) are systemic inflammatory disorders driven by dysregulated immune responses that can affect multiple organs, including the lungs.
- Trial name
- NCT07806045
- Testing
- nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qiubai Li
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum
Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum
This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum.
- Conditions
- Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
- Trial name
- NCT04060550
- Testing
- Xolair
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Osteoarthritis, Knee
Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF).
- Trial name
- NCT00941746
- Testing
- PG110
- Where
- Netherlands
- Volunteers
- 56 people
- Sponsor
- Abbott
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Transplant Recipients With Anti-HLA Antibodies
A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients
The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic…
- Trial name
- DSA (NCT02115503)
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Databean
Advanced Urothelial Carcinoma
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.
- Trial name
- MACOCUC-01 (NCT05738161)
- Testing
- Magrolimab, Cisplatin, Gemcitabine
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Giant Cell Arteritis, Takayasu's Arteritis
Reproductive Health in Men and Women With Vasculitis
The purpose of this study is to learn about reproductive health, including fertility and pregnancies, in people with vasculitis.
- Conditions
- Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis
- Trial name
- NCT02176070
- Where
- United States
- Volunteers
- 467 people
- Sponsor
- University of South Florida
Gastrointestinal Tumor, Solid Tumor
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, non-randomized Phase I clinical study with dose-escalation and expansion cohorts, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy…
- Trial name
- NCT07678970
- Testing
- SI-B036
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.